Target Validation Information
TTD ID T37693
Target Name Cannabinoid receptor 2 (CB2)
Type of Target
Successful
Drug Potency against Target Drug Info Ki = 4410 nM [25]
Drug Info Ki = 2040 nM [25]
(1R,2R)-N-Arachidonoylcyclopropanolamide Drug Info Ki = 240 nM [25]
(1R,2S)-N-Arachidonoylcyclopropanolamide Drug Info Ki = 190 nM [25]
(1R,2S)-N-Oleoylcyclopropanolamide Drug Info Ki = 1630 nM [25]
(1S,2S)-N-Arachidonoylcyclopropanolamide Drug Info Ki = 290 nM [25]
(1S,2S)-N-Oleoylcyclopropanolamide Drug Info Ki = 2420 nM [25]
(2R)-N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-2-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX) Drug Info IC50 = 3450 nM [32]
(2R)-N-(7'-(2-CHLOROPHENYL)-6'-(4-CHLOROPHENYL)-3',4'-DIHYDROSPIRO[CYCLOHEXANE-1,2'-PYRANO[2,3-B]PYRIDINE]-4'-YL)-2-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX) Drug Info IC50 = 3400 nM [32]
(2S)-N-(7'-(2-CHLOROPHENYL)-6'-(4-CHLOROPHENYL)-3',4'-DIHYDROSPIRO[CYCLOHEXANE-1,2'-PYRANO[2,3-B]PYRIDINE]-4'-YL)-2-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX) Drug Info IC50 = 10000 nM [32]
(4-benzhydrylpiperazin-1-yl)(cyclohexyl)methanone Drug Info Ki = 3050 nM [29]
(E)-N-(3,5-dimethoxyphenethyl)undec-2-enamide Drug Info Ki = 5200 nM [3]
(E)-N-(4-methoxyphenethyl)undec-2-enamide Drug Info Ki = 5100 nM [3]
(E)-N-(4-methoxyphenyl)undec-2-enamide Drug Info Ki = 2500 nM [3]
1,4-dihydroindeno[1,2-c]-pyrazole Drug Info Ki = 0.34 nM [5]
2'-amino-4-(1,1-dimethyl-heptyl)-biphenyl-2-ol Drug Info Ki = 17 nM [11]
2-(2-Methoxybenzyl)-3H-benzo[f]chromen-3-one Drug Info Ki = 2060 nM [24]
3'-amino-4-(1,1-dimethyl-heptyl)-biphenyl-2-ol Drug Info Ki = 44 nM [11]
3-benzoyl-1-pentyl-1,4-dihydroquinolin-4-one Drug Info Ki = 446 nM [13]
3-Benzyl-5-isopropyl-8-methylchromen-2-one Drug Info Ki = 4270 nM [24]
4'-(1,1-dimethyl-heptyl)-3,5-dimethyl-biphenyl Drug Info Ki = 2138 nM [11]
4'-amino-4-(1,1-dimethyl-heptyl)-biphenyl-2-ol Drug Info Ki = 1000 nM [11]
4-(1,1-dimethyl-heptyl)-2'-methoxy-biphenyl-2-ol Drug Info Ki = 1 nM [11]
4-(1,1-dimethyl-heptyl)-3'-methoxy-biphenyl-2-ol Drug Info Ki = 580 nM [11]
4-benzhydryl-N-butylpiperazine-1-carboxamide Drug Info Ki = 2833 nM [29]
4-benzhydryl-N-cyclohexylpiperazine-1-carboxamide Drug Info Ki = 2407 nM [29]
5-(1,1-dimethyl-heptyl)-2-pyridin-3-yl-phenol Drug Info Ki = 20 nM [11]
5-Biphenyl-4-ylmethyl-1-isobutyl-1H-tetrazole Drug Info Ki = 7700 nM [17]
5-Biphenyl-4-ylmethyl-2-isobutyl-2H-tetrazole Drug Info Ki = 4700 nM [17]
5-Methoxy-3-(2-methoxybenzyl)-2H-chromen-2-one Drug Info Ki = 3490 nM [24]
6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX) Drug Info IC50 = 2480 nM [32]
6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-((R)-1-HYDROXYETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX) Drug Info IC50 = 2330 nM [32]
6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(1-HYDROXY-2-METHYLPROPAN-2-YL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX) Drug Info IC50 = 7450 nM [32]
6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(HYDROXYMETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX) Drug Info IC50 = 3390 nM [32]
A-796260 Drug Info Ki = 4.6 nM [27]
AM-1241 Drug Info Ki = 11.5 nM [27]
AM-1710 Drug Info Ki = 6.7 nM [16]
AM-1714 Drug Info Ki = 0.82 nM [16]
AM-1715 Drug Info Ki = 5.9 nM [16]
AM-281 Drug Info Ki = 4200 nM [24]
AM-404 Drug Info Ki = 1300 nM [21]
AM-411 Drug Info Ki = 52 nM [33]
AM-4768 Drug Info Ki = 4.8 nM [16]
AM-630 Drug Info Ki = 36 nM [15]
Cis-N-oleoylcyclopropanolamide Drug Info Ki = 340 nM [25]
DELTA 8-TETRAHYDROCANNOBINOL Drug Info Ki = 39.3 nM [20]
Dodeca-2E,4E-dienoic acid isobutylamide Drug Info Ki = 52 nM [10]
GNF-PF-5188 Drug Info Ki = 1.78 nM [23]
JWH-120 Drug Info Ki = 6.1 nM [23]
JWH-133 Drug Info Ki = 65 nM [8]
JWH-145 Drug Info Ki = 6.4 nM [7]
JWH-146 Drug Info Ki = 62 nM [7]
JWH-147 Drug Info Ki = 7.1 nM [7]
JWH-150 Drug Info Ki = 15 nM [7]
JWH-151 Drug Info Ki = 30 nM [23]
JWH-156 Drug Info Ki = 104 nM [7]
JWH-167 Drug Info Ki = 159 nM [1]
JWH-201 Drug Info Ki = 444 nM [1]
JWH-202 Drug Info Ki = 645 nM [1]
JWH-203 Drug Info Ki = 7 nM [1]
JWH-204 Drug Info Ki = 25 nM [1]
JWH-205 Drug Info Ki = 180 nM [1]
JWH-206 Drug Info Ki = 498 nM [1]
JWH-207 Drug Info Ki = 3723 nM [1]
JWH-208 Drug Info Ki = 570 nM [1]
JWH-209 Drug Info Ki = 1353 nM [1]
JWH-229 Drug Info Ki = 18 nM [23]
JWH-237 Drug Info Ki = 106 nM [1]
JWH-243 Drug Info Ki = 41 nM [7]
JWH-244 Drug Info Ki = 18 nM [7]
JWH-245 Drug Info Ki = 25 nM [7]
JWH-246 Drug Info Ki = 16 nM [7]
JWH-248 Drug Info Ki = 657 nM [1]
JWH-249 Drug Info Ki = 20 nM [1]
JWH-250 Drug Info Ki = 33 nM [1]
JWH-251 Drug Info Ki = 146 nM [1]
JWH-252 Drug Info Ki = 19 nM [1]
JWH-253 Drug Info Ki = 84 nM [1]
JWH-268 Drug Info Ki = 40 nM [23]
JWH-292 Drug Info Ki = 20 nM [7]
JWH-293 Drug Info Ki = 41 nM [7]
JWH-294 Drug Info Ki = 3972 nM [14]
JWH-295 Drug Info Ki = 3759 nM [14]
JWH-296 Drug Info Ki = 2060 nM [14]
JWH-297 Drug Info Ki = 1506 nM [14]
JWH-302 Drug Info Ki = 89 nM [1]
JWH-303 Drug Info Ki = 138 nM [1]
JWH-305 Drug Info Ki = 29 nM [1]
JWH-306 Drug Info Ki = 82 nM [1]
JWH-307 Drug Info Ki = 3.3 nM [7]
JWH-308 Drug Info Ki = 33 nM [7]
JWH-309 Drug Info Ki = 49 nM [7]
JWH-311 Drug Info Ki = 39 nM [1]
JWH-312 Drug Info Ki = 91 nM [1]
JWH-313 Drug Info Ki = 365 nM [1]
JWH-314 Drug Info Ki = 76 nM [1]
JWH-315 Drug Info Ki = 182 nM [1]
JWH-323 Drug Info Ki = 639 nM [14]
JWH-324 Drug Info Ki = 231 nM [34]
JWH-325 Drug Info Ki = 700 nM [14]
JWH-337 Drug Info Ki = 238 nM [14]
JWH-343 Drug Info Ki = 1362 nM [14]
JWH-344 Drug Info Ki = 221 nM [14]
JWH-345 Drug Info Ki = 173 nM [14]
JWH-346 Drug Info Ki = 39 nM [7]
JWH-347 Drug Info Ki = 169 nM [7]
JWH-348 Drug Info Ki = 53 nM [7]
JWH-363 Drug Info Ki = 71 nM [7]
JWH-364 Drug Info Ki = 29 nM [7]
JWH-365 Drug Info Ki = 3.4 nM [7]
JWH-366 Drug Info Ki = 24 nM [7]
JWH-367 Drug Info Ki = 23 nM [7]
JWH-368 Drug Info Ki = 9.1 nM [7]
JWH-369 Drug Info Ki = 5.2 nM [7]
JWH-370 Drug Info Ki = 4 nM [7]
JWH-371 Drug Info Ki = 64 nM [7]
JWH-372 Drug Info Ki = 8.2 nM [7]
JWH-373 Drug Info Ki = 69 nM [7]
JWH-385 Drug Info Ki = 421 nM [14]
JWH-392 Drug Info Ki = 1782 nM [14]
JWH-401 Drug Info Ki = 1120 nM [14]
JWH-402 Drug Info Ki = 1077 nM [14]
JWH-403 Drug Info Ki = 460 nM [14]
JWH-404 Drug Info Ki = 672 nM [14]
JWH-405 Drug Info Ki = 154 nM [14]
JWH-406 Drug Info Ki = 215 nM [14]
JWH-407 Drug Info Ki = 546 nM [14]
JWH-440 Drug Info Ki = 553 nM [34]
JWH-441 Drug Info Ki = 808 nM [34]
JWH-442 Drug Info Ki = 693 nM [34]
KM-233-M Drug Info Ki = 0.9 nM [18]
N-(1H-indazol-5-yl)icosa-5,8,11,14-tetraenamide Drug Info Ki = 1000 nM [21]
N-(2-chloroethyl)icosa-5,8,11,14-tetraenamide Drug Info Ki = 95 nM [15]
N-(3,3-Diphenyl)propyl-2,2-diphenylacetamide Drug Info Ki = 7900 nM [19]
N-(3-Phenyl)propyl-2-(4-bromophenylacetamide) Drug Info Ki = 1800 nM [19]
N-(4-hydroxybenzyl)icosa-5,8,11,14-tetraenamide Drug Info Ki = 100 nM [21]
N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-2-HYDROXYACETAMIDE (ENANTIOMERIC MIX) Drug Info IC50 = 6610 nM [32]
N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-3-HYDROXY-2,2-DIMETHYLPROPANAMIDE (ENANTIOMERIC MIX) Drug Info IC50 = 7600 nM [32]
N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-3-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX) Drug Info IC50 = 5400 nM [32]
N-(7'-(2-CHLOROPHENYL)-6'-(4-CHLOROPHENYL)-3',4'-DIHYDROSPIRO[CYCLOHEXANE-1,2'-PYRANO[2,3-B]PYRIDINE]-4'-YL)-2-HYDROXY-2-METHYLPROPANAMIDE (ENANTIOMERIC MIX) Drug Info IC50 = 12000 nM [32]
N-(7-(2-CHLOROPHENYL)-6-(4-CHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-2-HYDROXYACETAMIDE (ENANTIOMERIC MIX) Drug Info IC50 = 10130 nM [32]
N-arachidonoyl-N-(2-hydroxyethyl)hydroxylamine Drug Info Ki = 1900 nM [6]
N-arachidonoyl-O-(2-hydroxyethyl)hydroxylamine Drug Info Ki = 81 nM [6]
N-benzyl-4-bromo-3-(morpholinosulfonyl)benzamide Drug Info Ki = 800 nM [22]
N-oleoyl-N-(2-hydroxyethyl)hydroxylamine Drug Info Ki = 5400 nM [6]
N-oleoyl-O-(2-hydroxyethyl)hydroxylamine Drug Info Ki = 3800 nM [6]
N-[6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDINE-4-YL]-4,4,4-TRIFLUORO-3-HYDROXYBUTANAMIDE (DIASTEREOMERIC MIX) Drug Info IC50 = 220 nM [31]
N1-(4-bromophenyl)-N2,N2-dipentylphthalamide Drug Info Ki < 25 nM [23]
NABILONE Drug Info Ki = 1.8 nM [35]
NAPHTHYRIDINONE Drug Info IC50 = 4100 nM [4]
O-arachidonoyl-N-(2-hydroxyethyl)hydroxylamine Drug Info Ki = 2400 nM [6]
O-oleoyl-N-(2-hydroxyethyl)hydroxylamine Drug Info Ki = 8600 nM [6]
PRAVADOLINE Drug Info IC50 = 3155 nM
Rac-cis-N-arachidonoylcyclopropanolamide Drug Info Ki = 150 nM [25]
Rac-trans-N-oleoylcyclopropanolamide Drug Info Ki = 380 nM [25]
SCH-225336 Drug Info Ki = 4.5 nM [30]
SCH-356036 Drug Info Ki = 0.8 nM [28]
SR-147778 Drug Info Ki = 442 nM [2]
VER-156084 Drug Info Ki = 7190 nM [26]
VER-156085 Drug Info Ki = 10900 nM [26]
WIN-55212-2 Drug Info IC50 = 2200 nM [12]
[3H]CP55940 Drug Info Ki = 1.11 nM [9]
Action against Disease Model SR141716A Drug Info N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide hydrochloride (SR141716A), a cannabinoid CB(2) receptor antagonist, has inverse agonist effects in cannabinoid CB(2) receptor-expressing cell lines, brain and peripheral organs. [36]
References
REF 1 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3.
REF 2 The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. J Med Chem. 2005 Aug 11;48(16):5059-87.
REF 3 New metabolically stable fatty acid amide ligands of cannabinoid receptors: Synthesis and receptor affinity studies. Bioorg Med Chem Lett. 2006 Jan 1;16(1):138-41.
REF 4 Synthesis of functionalized 1,8-naphthyridinones and their evaluation as novel, orally active CB1 receptor inverse agonists. Bioorg Med Chem Lett. 2006 Feb;16(3):681-5.
REF 5 Tricyclic pyrazoles. 3. Synthesis, biological evaluation, and molecular modeling of analogues of the cannabinoid antagonist 8-chloro-1-(2',4'-dichl... J Med Chem. 2005 Nov 17;48(23):7351-62.
REF 6 Oxyhomologues of anandamide and related endolipids: chemoselective synthesis and biological activity. J Med Chem. 2006 Apr 6;49(7):2333-8.
REF 7 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5.
REF 8 Design, synthesis, and biological evaluation of new 1,8-naphthyridin-4(1H)-on-3-carboxamide and quinolin-4(1H)-on-3-carboxamide derivatives as CB2 ... J Med Chem. 2006 Oct 5;49(20):5947-57.
REF 9 Tricyclic pyrazoles. 4. Synthesis and biological evaluation of analogues of the robust and selective CB2 cannabinoid ligand 1-(2',4'-dichlorophenyl... J Med Chem. 2006 Dec 14;49(25):7502-12.
REF 10 Self-assembling cannabinomimetics: supramolecular structures of N-alkyl amides. J Nat Prod. 2007 Jun;70(6):1010-5.
REF 11 Biaryl cannabinoid mimetics--synthesis and structure-activity relationship. Bioorg Med Chem Lett. 2007 Jul 1;17(13):3652-6.
REF 12 Synthesis and cannabinoid activity of 1-substituted-indole-3-oxadiazole derivatives: novel agonists for the CB1 receptor. Eur J Med Chem. 2008 Mar;43(3):513-39.
REF 13 Pharmacomodulations around the 4-oxo-1,4-dihydroquinoline-3-carboxamides, a class of potent CB2-selective cannabinoid receptor ligands: consequence... J Med Chem. 2007 Nov 1;50(22):5471-84.
REF 14 Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35.
REF 15 New 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6505-10.
REF 16 Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity. J Med Chem. 2007 Dec 27;50(26):6493-500.
REF 17 New tetrazole-based selective anandamide uptake inhibitors. Bioorg Med Chem Lett. 2008 May 1;18(9):2820-4.
REF 18 Exploring the substituent effects on a novel series of C1'-dimethyl-aryl Delta8-tetrahydrocannabinol analogs. Bioorg Med Chem. 2008 Jul 1;16(13):6489-500.
REF 19 Novel sterically hindered cannabinoid CB1 receptor ligands. Bioorg Med Chem. 2008 Aug 1;16(15):7510-5.
REF 20 Bornyl- and isobornyl-Delta8-tetrahydrocannabinols: a novel class of cannabinergic ligands. J Med Chem. 2008 Oct 23;51(20):6393-9.
REF 21 New analgesics synthetically derived from the paracetamol metabolite N-(4-hydroxyphenyl)-(5Z,8Z,11Z,14Z)-icosatetra-5,8,11,14-enamide. J Med Chem. 2008 Dec 25;51(24):7800-5.
REF 22 CB2 selective sulfamoyl benzamides: optimization of the amide functionality. Bioorg Med Chem Lett. 2009 Jan 15;19(2):309-13.
REF 23 Discovery of novel CB2 receptor ligands by a pharmacophore-based virtual screening workflow. J Med Chem. 2009 Jan 22;52(2):369-78.
REF 24 Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists. Bioorg Med Chem. 2009 Apr 1;17(7):2842-51.
REF 25 Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes. J Med Chem. 2009 May 14;52(9):3001-9.
REF 26 Fatty acid amide hydrolase inhibitors. Surprising selectivity of chiral azetidine ureas. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4241-4.
REF 27 Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity. J Med Chem. 2010 Jan 14;53(1):295-315.
REF 28 Synthesis and SAR of novel imidazoles as potent and selective cannabinoid CB2 receptor antagonists with high binding efficiencies. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1084-9.
REF 29 Discovery of benzhydrylpiperazine derivatives as CB1 receptor inverse agonists via privileged structure-based approach. Eur J Med Chem. 2010 Mar;45(3):1133-9.
REF 30 Radiosynthesis of novel carbon-11-labeled triaryl ligands for cannabinoid-type 2 receptor. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1565-8.
REF 31 Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carbox... J Med Chem. 2010 May 27;53(10):4028-37.
REF 32 Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4.
REF 33 Heteroadamantyl cannabinoids. J Med Chem. 2010 Aug 12;53(15):5656-66.
REF 34 Synthesis and pharmacology of 1-methoxy analogs of CP-47,497. Bioorg Med Chem. 2010 Aug 1;18(15):5475-82.
REF 35 Novel 1',1'-chain substituted hexahydrocannabinols: 9-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid r... J Med Chem. 2010 Oct 14;53(19):6996-7010.
REF 36 Inhibitory effects of SR141716A on G-protein activation in rat brain. Eur J Pharmacol. 2001 Mar 2;414(2-3):135-43.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.